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HIGH DIAGNOSTIC EFFICIENCY OF IGM-ELISA WITH THE USE OF MULTIPLE ANTIGEN PEPTIDES 
(MAP1) FROM T. gondii ESA (SAG-1, GRA-1 AND GRA-7), IN ACUTE TOXOPLASMOSIS
Patrícia Regina Barboza ARAÚJO(1) & Antonio Walter FERREIRA(1) 
SUMMARY
The main serological marker for the diagnosis of recent toxoplasmosis is the specific IgM antibody, along with IgG antibodies of 
low avidity. However, in some patients these antibodies may persist long after the acute/recent phase, contributing to misdiagnosis 
in suspected cases of toxoplasmosis. In the present study, the diagnostic efficiency of ELISA was evaluated, with the use of peptides 
derived from T. gondii ESA antigens, named SAG-1, GRA-1 and GRA-7. In the assay referred to, we studied each of these peptides 
individually, as well as in four different combinations, as Multiple Antigen Peptides (MAP), aiming to establish a reliable profile for 
the acute/recent toxoplasmosis with only one patient serum sample. The diagnostic performance of the assay using MAP1, with the 
combination of SAG-1, GRA-1 and GRA-7 peptides, demonstrated better discrimination of the acute/recent phase from non acute/
recent phase of toxoplasmosis. Our results show that IgM antibodies to MAP1 may be useful as a serological marker, enhancing the 
diagnostic efficiency of the assay for acute/recent phase of toxoplasmosis.
KEYWORDS: Toxoplasmosis; Serology; MAPs; ESA.
INTRODUCTION
Toxoplasmosis is a prevailing infection among humans and other 
warm-blooded animals, caused by an intracellular protozoa, Toxoplasma 
gondii. There is a significant danger to the fetuses of mothers who acquire 
the infection during pregnancy, and it has been established as a cause 
of life-threatening disease in immunocompromised individuals. The 
diagnosis of T. gondii infection is of considerable importance, because 
there are specific anti-T. gondii therapies. Serological diagnosis of acute 
Toxoplasmosis has traditionally been made by detection of specific IgM 
antibodies or by the demonstration of a significant increase in specific 
IgG antibody levels, or both. Because specific IgM antibodies can 
persist for several months, or even years in some individuals, following 
acute infection, interpretation of serological tests might be troublesome 
when acute Toxoplasmosis is suspected9. The diagnosis of chronic 
stage of infection or of past exposure to T. gondii is made by detection 
of specific IgG antibodies and the absence of the acute-phase markers 
IgM and IgA22. The currently available commercial tests to detect IgG, 
IgM and IgA antibodies rely mostly on preparations of crude parasite 
antigens, i.e. with tachyzoites harvested from infected mice or cell 
cultures. However, the use of whole-tachyzoites antigens can result in 
false-positive reactions thereby reducing the clinical value based on 
serological data9,11,13,28. Tachyzoite antigens are obtained differently in 
respect to their source and process for their collection and purification. 
These facts imply that the reactivity among antigens may vary greatly, 
contributing to inaccurate provision of diagnostic efficiency by assay 
systems. Several reports1,2,4,6,7,10,16,23,27,29 have emphasized the value of the 
detection of specific antibodies raised to excreted-secreted antigens (ESA) 
of T. gondii for the diagnosis of acute toxoplasmosis. The T. gondii ESA 
constitutes 90% of the circulating antigens in infected humans, thus is 
one of the first targets of the host immune response6.
Recombinant antigens and synthetic peptides have been prepared 
from ESA antigens, however, the exact composition and association of 
recombinant antigens and peptides to be used in immunoassays to detect 
toxoplasma antibodies is still an open question. The identification of 
human immunodominant B-cell epitopes within the T. gondii antigens 
can help to find those antigens involved in the specicific B-cell response, 
and they will be useful for immunoassays to detect anti-toxoplasma 
antibodies15,25,28. TAM32 described in 1988 a novel immunological 
approach, consisting of some immunodominant sequences of peptides 
associated by means of a small peptidyl core matrix (multiple Antigen 
Peptide - MAP). This association presents several advantages such as: 
the antigen composition of the test being precisely known, being able to 
use more than one defined antigens; immunogenicity, antigenicity and 
possibility for easy standardization of the method. So, multiple antigen 
peptides may be an alternative source of antigens that are characteristic 
of the acute or chronic stages of the infection, serving as a tool to 
discriminate the acute/recent toxoplasmosis from chronic stages. The 
design of MAP chosen for study by above authors consisted of a core 
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matrix with heptalysine containing three dendritic arms of T. gondii ESA 
peptides in length. The ESA peptides chosen were granule protein 1 GRA-
1) correlated with chronic toxoplasmosis, granule protein 7 (GRA-7) 
detected in acute toxoplasmosis16,22 and surface antigen 1 (SAG-1) present 
only in the tachyzoite stage and marker of acute toxoplasmosis2,7,26. In the 
present study, we evaluated the diagnostic efficiency of ELISA with the 
use of SAG1, GRA1 and GRA7 peptides derived from T. gondii ESA, 
individually and in combined forms as MAP, for the detection of IgG, 
IgM and IgA antibodies, aiming to establish a profile of acute/recent 
toxoplasmosis, with a single serum sample.
MATERIAL AND METHODS
Serum samples. A total of 300 serum samples was obtained from 
individuals during routine screening for Toxoplasmosis and analyzed 
by a commercially available kit for ELISA (VIDAS BioMérieux-
Brazil) and classic serological methods (indirect immunofluorescence 
assay (IFA) (BioMérieux-Brazil) and indirect hemagglutination assay 
(HAI) (BioMérieux-Brazil) to detect IgM and IgG antibodies, anti-T. 
gondii and avidity of specific IgG antibodies. Sera were selected as 
previously described by FERREIRA & CAMARGO9; MONTOYA24 
and PIETKIEWICZ et al.28, based on clinical and serological data. Five 
groups were studied according to the clinical and serological findings as 
follows. Group I comprised 25 patients, presenting clinical and serological 
symptoms compatible with acute or acute/recent toxoplasmosis. They 
exhibited specific IgM antibodies (titer ≥ 64), IgG antibodies (titer ≤ 128) 
by IFA and HAI, and low avidity of T. gondii-specific IgG. Serum samples 
were positive for T. gondii-specific IgG and IgM by automated ELISA 
assay. Group II had 25 patients, without clinical symptoms or serological 
profiles of non-acute/recent toxoplasmosis. They showed specific IgM 
antibodies (titer <64), IgG antibodies (titer ≥ 28) by IFA and HAI, and 
high avidity of T. gondii-specific IgG. Serum samples were positive for 
T. gondii-specific IgG and IgM by automated ELISA assay. Group III 
included 100 individuals, exhibiting specific IgG antibodies (titer ≥ 256) by 
IFA and HAI, negative results for T. gondii-specific IgM by IFA and HAI, 
and high avidity of T. gondii-specific IgG. Serum samples were positive 
for IgG and negative for IgM T. gondii-specific by ELISA automated 
assay. No patient presented clinical symptoms, but, serological data was 
suggestive of past toxoplasmosis. Group IV consisted of 100 clinically 
healthy controls without present or previous serological data suggesting 
toxoplasmosis, i.e. neither IgM nor IgG antibodies were detected by IFA, 
HAI or ELISA automated assay. Group V had 50 patients with unrelated 
infections, but who had defined clinical and serological diagnosis of rubella 
(10), mononucleosis (10), cytomegalovirus (10), malaria (10) and Chagas 
disease (10). The ethical committee of the Institute of Tropical Medicine, 
University of São Paulo approved the project.
ESA. T. gondii T. gondii tachyzoites, RH strain, were obtained 
from the peritoneal cavity of Balb/c mice infected two days earlier and 
inoculated into culture of human fibroblast cells for three hours at 37 °C. 
The culture supernatants were centrifuged at 1000xg for 10 minutes and 
filtered through 0.22-mm-pore-size membrane (Millipore Corporation, 
Bedford, Massachusetts). The ESA was stored at -70 °C with 100 U/mL 
aprotinin (Sigma Chemical Co, St. Louis, Missouri).
Viability of tachyzoites and protein concentration. After washing 
three times with PBS pH 7.2, the culture of human fibroblasts was 
inoculated with 1 x 108 tachyzoites and incubated at 37 °C. Five-milliliter 
aliquots of culture were taken at various intervals from 1, 2, 3, 4, 5, 6, 
12 and 24 hours post-infection. The number and viability of tachyzoites 
were evaluated in these aliquots by the Tripan blue method and the 
protein concentration was determined using the Bio-RAD DC Protein 
Assay (France). 
PAGE. The ESA was eletrophoresed in polyacrylamide slab gel using 
a discontinuous sodium dodecyl sulfate (SDS) buffer system as described 
by LAEMMLI20, with an 18% running gel and 3% stacking gel. The 
running buffer contained 25mM TRIS, 192mM glycine, and 0.1% SDS 
at pH 8.3. Gels were run at 5-6 V/cm until the bromophenol blue marker 
reached the bottom. Molecular weight markers (Full Range RainbowTM, 
Amersham Life Sciences, UK) were used to plot the calibration curve. 
Proteins were transferred from SDS slab gel to a polyvinyllidene 
difluoride membrane (Immobilon PVDF, Millipore, USA).
Synthesis of SAG-1, GRA-1 and GRA-7 peptides. The SAG-1, 
GRA-1 and GRA-7 peptides were synthesized from PVDF membrane 
obtained after T. gondii ESA proteins eletrophoresed as above on 
Tentagel S resin (Rapp Polymere GmbH, Tubingen, Germany) by using 
a Rainin Symphony Multiplex synthesizer (Protein Technology, Tucson, 
Arizona) with standard 9-7 fluorenylmethoxycarbonyl (Fmoc) chemistry. 
Standard double couplings were performed by using a fourfold excess 
of Fmoc-protected amino acids active in situ with equimolar amounts 
of N-hydroxybenzotriazole and 2-(1 H-benzotriazole-1-yl)-1,1,3,3-
tertamethyluronium tertafluoroborate twice for 20 minutes each time. The 
Fmoc protecting group was removed by using a mild base treatment with 
2% piperidine 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in dimethyl 
sulfoxide-70% domethylformamide with in situ activation. The peptide 
sequence chosen for SAG-1 is based in KATO et al.19; for GRA-1 in 
BEGHETTO et al.3; and for GRA-7 in SOUSA et al.31. 
MAP: Combination of SAG-1, GRA-1 and GRA-7 peptides. 
After the synthesis completion, the peptide was cleaved from the resin by 
incubation for 2.5 hours with 90% trifluoroacetic acid-5% thioanisole-3% 
ethanedithiol-2% anisole. The peptide was precipitated from the mixture 
by using t-butyl methyl ether. After centrifugation, the pellet was washed 
three times with t-butyl methyl ether and dried overnight in a vacuum 
(TAM32). The purity of the crude peptide was checked by reverse-phase 
high-performance liquid chromatography, lyophilized, and stored at 4 °C 
until use.
 ELISA with individual peptides (SAG-1, GRA-1 and GRA-7). 
Microtiter plate (Immuno Plate Maxisorp; Nunc) wells were coated 
overnight at room temperature with 50 mL of each of the peptides SAG-1, 
GRA-1 or GRA-7 diluted in 0.05 M carbonate buffer (pH 9.6) at the optimal 
concentration of 10 mg/mL determined by block titration. After coating, the 
wells were washed three times with PBS/0.25% Tween 20 (PBS-T) and 
blocked with 200 mL of 5% skim milk in PBS-T (blocking solution) for 
two hours at 37°C. The plates were then washed as described above and 
100 µL of test or control serum were applied to each well. To test for IgG, 
the sera were diluted 1:100 in blocking solution. In the case of IgM or IgA 
detection, the sera were diluted at the optimal 1:25 in blocking solution, 
as determined by previous block titration. The plates were incubated for 
two hours at room temperature and washed as described above. Goat anti-
human IgG, IgM, or IgA peroxidase-labeled antibodies (Sigma Chemical 
Co., St Louis, Missouri) diluted 1:200 were used as the secondary antibody. 
After being incubated for one hour at room temperature and washings, 
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immune complexes were developed with ortho-phenylenediamine as 
the chromogenic substrate. Ate reactivity was measured at 490 nm in an 
automatic enzyme-linked immunosorbent assay (ELISA) reader (Reader 
230S- Anthos). Each serum was assayed in duplicate by ELISA. For each 
peptide the cut-off level was determined according to the mean value of 
optical density (plus three standard deviations) of the negative controls.
ELISA with MAPs. Each microtiter plate well (Immuno Plate 
Maxisorp; Nunc) was coated overnight at room temperature with 100 
mL of the MAP1, MAP2, MAP3 or MAP4 diluted in 0.05 M carbonate 
buffer (pH 9.6) at the optimal concentration of 5 mg/mL found by 
block titration. After coating, the wells were washed three times with 
PBS/0.25% Tween 20 (PBS-T) and blocked with 200 mL of 5% skim 
milk in PBS-T (blocking solution) for two hours at 37 °C. The plates 
were then washed as described above and 100 µL of test or control 
serum were applied to each well. For the detection of IgG to MAP1, 
MAP2, MAP3 or MAP4, sera were diluted 1:200 in blocking solution. 
To detect IgM and IgA to MAP1, MAP2, MAP3 or MAP4, sera were 
diluted at 1:50 in blocking solution, as determined by block titration. The 
plates were incubated for two hours at room temperature and washed as 
described above. Goat anti-human IgG, IgM, or IgA peroxidase-labeled 
antibodies (Sigma Chemical Co., St Louis, Missouri) diluted 1:200 were 
used as the secondary antibody. After being incubated for one hour at 
room temperature and washings performed, immune complexes were 
developed with ortho-phenylenediamine as the chromogenic substrate. 
The reactivity was measured at 490 nm in an automatic enzyme-linked 
immunosorbent assay (ELISA) reader (Reader 230S- Anthos). Each 
serum was assayed in duplicate by ELISA. For each MAP the cut-off 
level was determined according to the mean value of optical density (plus 
three standard deviations) of the negative controls.
Diagnostic performance of ELISA using different peptides. The 
diagnostic parameters were defined in terms of sensitivity, specificity 
and efficiency, according to FERREIRA & AVILA (2001)8. The 
sensitivity was determined independently for groups I9(25), II(25) and 
III(100): (ELISA positive)/(Positive by conventional reference data). 
The specificity was calculated with the sum of results obtained from 
control groups IV(100) and V(50): (ELISA negative)/(Negative by 
reference data). For the diagnostic efficiency, in turn, the calculation was 
as follows: (ELISA positive + ELISA negative)/(Positive by reference 
data + Negative by reference data). The reference data corresponds to the 
aforementioned conventional clinical and serological findings.
RESULTS
A total of 300 serum samples belonging to five groups of patients 
was studied by ELISA, using each of three peptides independently and 
also in their four different combinations.
Reactivities of IgG, IgM and IgA antibodies with SAG-1, GRA-1 
and GRA-7 peptides. As shown in Table 1, IgG, IgM and IgA antibodies’ 
reaction to SAG-1, GRA-1 and GRA-7 were found in patients from group 
I, II and III. In terms of sensitivity, the IgG-ELISA using individually 
three different peptides varied from 98% to 68%. In the IgM-ELISA with 
the use of same peptides, the sensitivity varied from 88% to 5%. In the 
IgA-ELISA antibodies to these three peptides were observed in patients 
from group I and II, ranging from 92% to 12%. However in the group III, 
IgA antibodies were detected by the use of these antigens. In groups IV 
and V, specific IgG, IgM or IgA antibodies to SAG-1, GRA-1 or GRA-7 
peptides were not observed, indicating the absence of cross-reactivity 
by the assay. It is worth mentioning the cut-off values determined for 
the detection of specific antibodies. In the detection of IgG antibodies 
to different peptide antigens as isolate or associate forms, considering 
five patient groups, cut-offs varied from 0.258 to 0.421, while for the 
detection of IgM antibodies, cut-offs ranged from 0.145 to 0.188, and for 
IgA antibodies, from 0.111 to 0.127. The overall data demonstrates that 
reactivities of IgG, IgM and IgA antibodies with SAG-1 were higher in 
patients from group I of acute/recent toxoplasmosis than other groups. 
However in group II and III, only IgG antibodies were highly reactive 
with the same peptide.
Reactivities of IgG, IgM and IgA antibodies with the combination 
of peptides MAP1, MAP2, MAP3 and MAP4 by ELISA. All sera from 
patients with acute/recent toxoplasmosis (group I), anti-MAP1 (SAG-1, 
GRA-1 and GRA-7) were detected. Figure 1 shows that IgG antibodies 
from all 25 (100%) patients reacted with MAP1, and their positive 
values were far from the stipulated value of cut-off (0.258). In other 
words, the mean value of the 25 sera was 3.2, with standard deviation 
(SD) of 0.014. In addition, these 25 (100%) sera reacted with MAP1 by 
IgM-ELISA. The mean value found for these sera was 3.8 (SD 0.012). 
In respect to IgA-ELISA, 96% (24/25) sera were positive and their mean 
value was 3.5 (SD 0.013). All 25 sera from patients with non-acute/recent 
toxoplasmosis (group II) as shown in Figure 1, had IgG antibodies and 
Table 1
Sensitivity of IgG-, IgM- and IgA-ELISA with the use of SAG-1, GRA-1 and 
GRA-7 peptides and with their four different combinations  as MAP1, 2, 3 and 
4 for the diagnosis of human toxoplasmosis  
Antibodies to 
Peptide (S)
Group I
% Sensitivity
Group II
% Sensitivity
Group III
% Sensitivity
IgG to:
                SAG-1
                GRA-1
                GRA-7
                MAP1
                MAP2
                MAP3
                MAP4
88 (22/25)
76(19/25)
84 (21/25)
100 (25/25)
0 (0/25)
0 (0/25)
0 (0/25)
84 (21/25)
68(17/25)
76 (19/25)
100 (25/25)
0 (0/25)
0 (0/25)
0 (0/25)
98 (98/100)
97(97/100)
94 (94/100)
100 (100/100)
0 (0/25)
0 (0/25)
0 (0/25)
IgM to:
                SAG-1
                GRA-1
                GRA-7
                MAP1
                MAP2
                MAP3
                MAP4
88 (22/25)
52 (13/25)
88 (22/25)
100 (25/25)
0 (0/25)
0 (0/25)
0 (0/25)
16 (4/25)
44 (11/25)
24 (6/25)
0 (0/25)
-
-
-
5 (5/100)
13 (13/100)
6 (6/100)
0 (0/100)
-
-
-
IgA to:
                SAG-1
                GRA-1
                GRA-7
                MAP1
                MAP2
                MAP3
                MAP4
92 (23/25)
84 (21/25)
84 (21/25)
96 (24/25)
0 (0/25)
0 (0/25)
0 (0/25)
12 (3/25)
48 (12/25)
16 (4/25)
92 (23/25)
-
-
-
0 (0/100)
0 (0/100)
0 (0/100)
0 (0/100)
-
-
-
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their values were far above the cut-off level. The mean value of the 25 sera 
was 6.8 (SD 0.016). In this group, these 25 sera did not react with MAP1 
by IgM-ELISA. The mean value of the 25 sera was 0.4 (SD 0.018). On 
the other hand, 23/25 sera (92%) showed IgA reactivity against MAP1. 
The mean value of the 23 sera was 2.6 (SD 0.014). In all 100 sera from 
patients with chronic toxoplasmosis (group III), IgG antibodies reacted 
strongly with MAP1, and none of the positive results were close to the 
cut-off value. Their mean value was 9.2 (SD 0.016). In contrast, this 
group had no IgM and IgA antibodies reacting with MAP1. In control 
groups IV and V, there were no anti-MAP1 IgG, IgM and IgA, i.e., no 
cross-reactivity was observed in these groups (Fig. 2). As for the IgG-
ELISA using MAP2, MAP3 and MAP4, antibodies were not detected 
in any sera from groups I, II and III. The IgM-ELISA and IgA-ELISA 
did not detect antibodies to same antigens in any sera from group I. On 
the other hand, in sera from groups II and III, IgM and IgA antibodies 
to MAP2, MAP3 and MAP4 were found. In respect to groups IV and V, 
IgG, IgM and IgA antibodies were not seen, showing no cross-reactivity 
in any of the serum samples. Thus, it can be stressed that a maximum 
efficiency was observed by IgM-ELISA utilizing MAP1 antigen for the 
diagnosis of acute/recent toxoplasmosis.
DISCUSSION
A century has elapsed since the early studies of Sabin and Feldman 
about the diagnosis of Toxoplasmosis. Traditional manual laboratory 
methods, adequate for small routines, have been replaced with 
automated or semi-automated procedures involving little manipulation 
and risk of human error. These systems can be used for large routine 
volumes at a reasonable price. In addition, continuous scientific and 
technical evolution has led to decisive progress in diagnosis through the 
search of gold standard tests that will provide safe information about 
the real health status of the patient. For years, the serological profile 
defined by experienced investigators has been accepted in laboratory 
diagnostic routine. However, current laboratory practice using highly 
sensitive automated equipment has led to problems with the detection 
of parasite specific IgG and IgM antibodies12,33. Several authors have 
shown that IgM to T. gondii can be detected for a long period after 
the primary infection and false positivities with IgG to T. gondii have 
been reported which are non-significant and erroneously interpreted as 
positive results indicating acute infection and protection19. Research and 
development have continued to advance and new parameters have been 
developed for the diagnosis of toxoplasmosis in its different phases, 
such as the avidity test of IgG antibodies and detection of the parasite 
by a molecular method such as polymerase chain reaction (PCR). 
The IgG avidity determination is an important serological marker that 
can be used to distinguish between acute/recent and non-acute phase, 
from a single serum sample. However, low IgG avidity results may 
persist for as long as one year after the primary infection because of 
immunosuppressive conditions or anti-toxoplasma pharmacotherapy 
that may affect the kinetics of the IgG avidity maturation5,11,13,20,23. The 
PCR has been successfully used in immunocompromised patients, 
ocular toxoplasmosis and congenital toxoplasmosis. However, some 
problems can be observed in laboratory practice, such as false negative 
results after treatment with anti-toxoplasma drugs, low and focal 
distribution of parasites in the tissues or the presence of non-viable 
parasites in autolyzed tissue. Excreted and secreted antigen (ESA) 
of T. gondii has been used in detection of specific antibodies for the 
diagnosis of acute toxoplasmosis1,2,3,4,6,7,15,27. As previously mentioned, 
circulating antigens in infected humans are constituted by T. gondii 
ESA, and are one of the first targets of the host immune response26. 
In addition, the ESA plays a role in the persistent stimulation of cell-
mediated immunity in chronically infected healthy subjects. Several 
fractions from T. gondii ESA isolated or in combination have been 
used in the diagnosis of toxoplasmosis. Among the fractions of T. 
gondii ESA, surface antigen 1 (SAG-1) has been extensively studied. 
SAG-1 is the most immunodominant and stage-specific antigen present 
in tachyzoite stage and not in bradyzoite stage. SAG-1 is one of the 
first antigens recognized by IgM antibodies during acute/recent phase. 
However, as confirmed here with our previous2 data and that of others7,26, 
specific anti-SAG-1 antibodies can be detected in chronic toxoplasmosis 
and non-acute/recent phase. Other important ESA fractions used in 
various studies for the diagnosis of toxoplasmosis originate from 
granule-dense organelles (GRA-7). This antigen produces a strong 
antibody response in the acute phase of infection and is found in the 
parasitophorous vacuole and the cytoplasm of the tachyzoite-infected 
host cell, leading to immune recognition due to constant rupture of the 
Fig. 1 - Reactivity of IgG, IgM and IgA antibodies with MAP1 (SAG-1, GRA-1 and GRA-7) 
peptides, in the study of serum samples from group I, including patients with acute/recent 
toxoplasmosis, group II with non-acute/recent toxoplasmosis and group III with chronic 
toxoplasmosis, by ELISA.
Fig. 2 - Reactivity of IgG, IgM and IgA with MAP1 (SAG-1, GRA-1, GRA-7) peptides, by 
ELISA, in the study of serum samples of group IV, consisting of clinically healthy individuals, 
and group V, with unrelated pathologies. 
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cyst cells16. The granule-dense 1 antigen (GRA-1) reacts strongly with 
serum samples from pregnant women infected with T. gondii3 and, as 
we found here, with sera from chronic and acute/recent toxoplasmosis, 
as in reported16 data. The present study was undertaken since the exact 
composition and conformation of T. gondii ESA antigens to be used 
to detect IgG and IgM antibodies in an immunoassay remained an 
open question. The assay performance varies significantly due to the 
influence of factors such as the number of serological targets to be 
sequestered within internal organelles, as well as the method utilized 
for the parasite antigen preparation. Advances in molecular biology 
permitted the obtainment of purified antigens, being an attractive 
alternative to improving the sensitivity and specificity of serological 
tests, in particular, for the detection of IgM antibodies. In this context, 
the multimeric nature of the MAP constructs provides reproducible 
results and increased surface binding. MAPs may also improve the 
early detection of antibodies of low affinity, such as those of the IgM 
isotype, during the early phase of infections. Significant advances by 
many laboratories have led to applications of MAPs for serodiagnosis. 
MAP showed a sensitivity increase of >108-fold compared with 
peptide antigen in an enzyme-linked immunosorbent assay (ELISA)28. 
These results indicate that MAPs may be antigens of choice for solid 
phase based immunoassays and they also are a promising tool for 
serodiagnosis in naturally immunized or infected individuals28. In a 
recent study, NOYA et al.27 compared various antigenic preparations 
with MAP for the diagnosis of different infections and reported high 
sensitivity and specificity of assays at low cost. 
In this work, we evaluated the diagnostic efficiency of IgG, 
IgM- and IgA-ELISA, using a combination of SAG-1, GRA-1 and 
GRA-7 constructed by the MAP system, to establish a profile of acute 
toxoplasmosis in single serum samples. In other words, we searched 
for a serologic marker among IgG, IgM and IgA antibodies by the use 
of MAP1 peptides, and conferring on ELISA maximum diagnostic 
efficiency. We already mentioned that the SAG-1, GRA-1 and GRA-7 in 
individual analysis and the sensitivity of the IgG-, IgM- and IgA-ELISA 
was low, due to the false negative results observed in the study of group 
of patients I, II and III (Table 1). In addition, positivity observed in 
these same groups of patients, by means of the above referred to assays, 
did not permit discrimination of acute/recent toxoplasmosis from other 
phases of the infection (Table 1). The IgG-ELISA using independently 
the peptides GRA-1 and GRA-7, although showing good sensitivities 
for chronic toxoplasmosis, cannot be helpful as confirmatory assays, 
as referred to JACOBS et al.(1999)17 and BEGHETTO et al. (2001)3. 
Maximum specificity was observed in the control groups (IV and 
V) including clinically healthy individuals and others with unrelated 
pathologies. After the study of each fraction, we dealt with different 
peptide combinations: MAP1 (SAG-1, GRA-7 and GRA-1); MAP2 
(SAG-1 and GRA-1); MAP3 (SAG-1 and GRA-7) and MAP4 (GRA-1 
and GRA-7) to see their ability to react with IgG, IgM and IgA T. gondii 
by ELISA. In the initial evaluation of the different peptide combinations 
by the assay, we observed that when SAG-1 was present, as in the MAP1, 
the sensitivity and specificity in the detection of IgG, IgM and IgA 
antibodies in different toxoplasmosis phases was higher compared with 
those without SAG-1, as MAP4 (Table 1). Our results are consistent with 
the results of other investigators who have found that SAG-1 improves 
the sensitivity and specificity of serological assays19,25. In the study of 
other peptide combinations such as, MAP2, 3 and 4, the assay presented 
low diagnostic performance, and the acute/recent, non-acute/recent and 
chronic phase could not be distinguished as in the assay using MAP1. 
These results indicate that different proportions of SAG-1 peptides found 
in the ESA T. gondii will influence greatly the diagnosis features of the 
assay, in the routine diagnosis of acute/recent toxoplasmosis.
We analyzed the diagnostic efficiency of ELISA using MAP1 
peptides for the detecting of IgG, IgM and IgA antibodies in three 
different groups and we found an increase of the assay sensitivity, 
mainly in the detection of IgM antibodies. Therefore, the sensitivity 
and the specificity of IgM-ELISA for acute/recent toxoplasmosis were 
maximum (100%) and, consequently, its diagnostic efficiency. In contrast, 
the non-acute/recent toxoplasmosis group, in spite of presenting some 
residual IgM antibodies detectable by a commercial kit, IgM antibodies 
to MAP1 were demonstrated. NOYA et al.27 investigated the use of MAP 
in an assay for the diagnosis of unrelated pathologies and they found 
similar specificity and sensitivity as we did with MAP1. In study of 
PIETKIEWICZ et al.28 using recombinant (SAG-1, GRA-1 and GRA-7) 
antigens, the acute/recent and non-acute/recent phase of toxoplasmosis 
could not be discriminated. Our results indicate that MAP1 may be the 
antigen of choice for the use in solid phase based immunoassays and these 
are promising tools for the serodiagnosis of acute/recent toxoplasmosis. 
The combination of SAG-1, GRA-1 and GRA-7 peptides, derived from 
ESA T. gondii, as MAP1 system will be helpful in the laboratory practice 
to distinguish acute/recent from non-acute/recent toxoplasmosis, with 
a single serum sample.
RESUMO
Alta eficiência diagnóstica do IgM ELISA com o uso de múltiplos 
antígenos peptídicos (MAP1) de T. gondii ESA (SAG-1, GRA-1 e 
GRA-7) na toxoplasmose aguda
O principal marcador sorológico para o diagnóstico da toxoplasmose 
aguda ou recente são os anticorpos IgM específicos, a par de anticorpos 
IgG de baixa avidez. Entretanto em alguns pacientes, estes anticorpos 
podem persistir, ultrapassando o período da fase aguda/recente, 
contribuindo para erro diagnóstico em casos suspeitos de toxoplasmose. 
No presente estudo, a eficiência diagnóstica de ELISA foi avaliada, 
com o uso de frações ou peptídeos originados dos antígenos ESA de T. 
gondii, denominados de SAG-1, GRA-1 e GRA-7. No referido ensaio, 
estudamos cada uma destas frações isoladamente, como também em 
quatro diferentes combinações, ou múltiplos peptídeos antigênicos 
(MAP), visando estabelecer um perfil confiável para a toxoplasmose 
aguda/recente em amostra única de soro. A melhor eficiência diagnóstica 
do ensaio foi encontrada com o uso da combinação de peptídeos SAG-1, 
GRA-1 e GRA-7, denominada MAP1. A detecção de anticorpos IgG e 
IgM anti-MAP-1 apresentou melhores características diagnósticas para 
a diferenciação entre a fase aguda/recente da fase não aguda/recente 
na toxoplasmose. Nossos resultados mostram que anticorpos IgM 
anti-MAP-1 poderão prestar auxílio como um marcador sorológico, 
aumentando a eficiência diagnóstica do ensaio para a fase aguda/recente 
da toxoplasmose.
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